Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service superficial venous ablation cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (235 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 36 | 2,102 | 28% |
| 2020 | 18 | 1,294 | 30% |
| 2021 | 24 |
Radiofrequency, laser, and adhesive ablation of the saphenous veins; office and vein-clinic heavy. Professional codes (what the surgeon bills): CPT 36475, 36478, 36482.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 60% of the cases CMS names in Massachusetts; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 132 | 8,630−5.2%/yr | −5.2%/yr | 4.5 | 97% | 9,880 in 2030+2.3%/yr |
| New Jersey | 70 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 34 | 3,386−4.6%/yr | −4.6%/yr | 3.50.7× | 43% | 4,060 in 2030+3.1%/yr |
| Dialysis access |
Superficial venous ablation in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
| 2024 |
| 1,623 |
| 39% |
| 2025 est. | ≈ 1,460 | – |
| 2026 est. | ≈ 1,500 | – |
| 1,544 |
| 32% |
| 2022 | 31 | 1,712 | 35% |
| 2023 | 33 | 1,688 | 38% |
| 2024 | 31 | 1,623 | 39% |
| 2025 from claims | – | 1,456 1,337–1,541 | 40% |
| 2026 forecast | – | 1,500 1,319–1,731 | 39% |
| 2027 forecast | – | 1,524 1,303–1,816 | 40% |
| 2028 forecast | – | 1,548 1,292–1,896 | 40% |
| 2029 forecast | – | 1,573 1,285–1,973 | 40% |
| 2030 forecast | – | 1,598 1,280–2,048 | 40% |
In 2025, 6% hospital outpatient, 94% office. The share outside the hospital has moved +2 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 4,906−2.3%/yr |
| −2.3%/yr |
| 4.5 |
| 97% |
| 6,260 in 2030+4.1%/yr |
| Pennsylvania | 45 | 3,315−8.9%/yr | −8.9%/yr | 2.3 | 87% | 3,220 in 2030−0.5%/yr |
| Connecticut | 39 | 2,246−8.9%/yr | −8.9%/yr | 6.4 | 100% | 2,440 in 2030+1.4%/yr |
| Rhode Island | 5 | 302−2.7%/yr | −2.7%/yr | 3.1 | 100% | 410 in 2030+5.3%/yr |
| Maine | 3 | 188−9.3%/yr | −9.3%/yr | 1.1 | 100% | 430 in 2030+15%/yr |
| 31 |
| 2,905−7.2%/yr |
| −7.2%/yr |
| 3.20.5× |
| 22% |
| 3,070 in 2030+0.9%/yr |
| Carotid revascularization | 18 | 984−3.3%/yr | −3.3%/yr | 1.01.0× | 0% | 1,170 in 2030+2.9%/yr |
| Thrombectomy, IVC filters & venous stents | 2 | 738−0.4%/yr | −0.4%/yr | 0.80.6× | 9% | 740 in 2030+0.1%/yr |
| Aortic endografts (EVAR/TEVAR) | 1 | 350−5.5%/yr | −5.5%/yr | 0.40.8× | 0% | 390 in 2030+1.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Medtronic leads with 86% of company spending on these surgeons in 2025, −10 pts on 2024.
In 2025, 3 companies reported engagement with Massachusetts’s surgeons worth $14K in consulting, speaking, meals and travel tied to these products, about $450 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.